Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20319041 | 1.00 | SHBG (0.46) | SHBGEPHX1DPP4TP53SMN1; SMN2 | |
| SCHEMBL30142421 | 1.00 | SHBG (0.46) | SHBGEPHX1DPP4TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9196277 | 0.98 | SHBG (0.44) | SHBGEPHX1DPP4TP53SMN1; SMN2 | |
| SCHEMBL19578580 | 0.98 | SHBG (0.42) | SHBGEPHX1DPP4TP53SMN1; SMN2 | |
| SCHEMBL5384279 | 0.87 | — | — | |
| SCHEMBL8738301 | 0.87 | — | — | |
| SCHEMBL5806546 | 0.86 | SHBG (0.43) | SHBGEPHX1DPP4TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6082121 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL22321784 | 0.85 | — | — | |
| SCHEMBL2781157 | 0.85 | EPHX1 (0.48) | SHBGEPHX1DPP4TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101195711-B | Polyamic acid composition and alignment film prepared from same | DALI POLYMER CO LTD | 2012-07-04 | — | — | CN | claimed |
| CN-101195711-A | Polyamic acid composition and alignment film prepared from same | DALI POLYMER CO LTD (CN) | 2008-06-11 | — | — | CN | claimed |
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-111868842-B | Conductive paste with stable viscosity over time | 株式会社则武 | 2021-11-19 | — | — | CN | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| CN-111868842-A | Conductive paste with stable viscosity over time | 株式会社则武 | 2020-10-30 | — | — | CN | disclosed |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| CN-101195711-B | Polyamic acid composition and alignment film prepared from same | DALI POLYMER CO LTD | 2012-07-04 | — | — | CN | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-5686066-A | Polyaspartic acid Zwitterionic derivatives, preparation processes thereof, hair-treating compositions and cosmetic compositions | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0769532-A1 | Naphtholactamimide fluorescent dyes | Ciba SC Holding AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| EP-0767191-A2 | Polymer, preparation process thereof, hairtreating compositions and cosmetic compositions | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-04-09 | — | — | EP | disclosed |
| CN-1031059-C | 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in treatment of thrombotic and vasospastic disease | SQUIBB & SONS INC (US) | 1996-02-21 | — | — | CN | disclosed |
| US-5420283-A | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide | PFIZER INC. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0391652-B1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | SQUIBB & SONS INC (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0391652-A1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| CN-1043716-A | Be used for the treatment of the heterocycleamide prostaglandin analogue that thrombus and angiospastic 7-oxabicyclo heptyl replace | SQUIBB & SONS INC (US) | 1990-07-11 | — | — | CN | disclosed |
| US-4243681-A | VASODILATION, ANTISPASMODIC AGENTS; ANTICOAGULANTS | MEAD JOHNSON & COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | SHBG 660/4885EPHX1 818/4885DPP4 578/4885 |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | SHBG 660/4885EPHX1 818/4885DPP4 578/4885 |
| US-12152014-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | SHBG 660/4885EPHX1 818/4885DPP4 578/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | SHBG 660/4885EPHX1 818/4885DPP4 578/4885 |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | SHBG 660/4885EPHX1 818/4885DPP4 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.